Aegis Boosts PT on PharmAthene (PIP) to $6; Sees NPV of Lump Sum at ~$220M
Tweet Send to a Friend
Aegis Capital boosts its price target on PharmAthene (AMEX: PIP) from $4 to $6 and maintains a Buy rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
